Grant: CIHR Fellowship
Direct Payment
$141,667.00
Modeling hypertrophic cardiomyopathy using human iPS cell-derived cardiomyocytes
FY 2012-13
Summary
Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden cardiac death in young adults and athletes. HCM is a condition with familial patterns of inheritance that result in left ventricular and/or septal hypertrophy, leading to reduced cardiac output and arrhythmias. It is also the most common inherited form of cardiovascular disease, with a prevalence estimated to be as high as 1 in 500 people. The majority of mutations that cause HCM have been identified in sarcomeric proteins that are required for cardiomyocyte contraction. However, the molecular mechanisms that lead to the development of HCM remain unknown. Due to fundamental differences in physiology and genetic makeup between humans and animal models, the study of HCM in the most physiologically relevant human cellular model to date (induced pluripotent stem cell-derived cardiomyocytes) will provide new mechanistic insights into disease pathology that is not attainable using animal models. This study will improve our understanding of the pathological mechanisms underlying HCM and could eventually lead to improved treatment options for HCM patients. Future efforts will be aimed at establishing high-throughput cellular platforms for analysis and compound testing to screen drugs for safety and efficacy.
Department
Program
CIHR Fellowship
Recipient
Location
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
282155
Name
Mandegar Mohammad A
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Modeling hypertrophic cardiomyopathy using human iPS cell-derived cardiomyocytes
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$141,667
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cardiovascular Genetics; Molecular Biology; Pharmacology; Stem Cell Biology
Abstract
Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden cardiac death in young adults and athletes. HCM is a condition with familial patterns of inheritance that result in left ventricular and/or septal hypertrophy, leading to reduced cardiac output and arrhythmias. It is also the most common inherited form of cardiovascular disease, with a prevalence estimated to be as high as 1 in 500 people. The majority of mutations that cause HCM have been identified in sarcomeric proteins that are required for cardiomyocyte contraction. However, the molecular mechanisms that lead to the development of HCM remain unknown. Due to fundamental differences in physiology and genetic makeup between humans and animal models, the study of HCM in the most physiologically relevant human cellular model to date (induced pluripotent stem cell-derived cardiomyocytes) will provide new mechanistic insights into disease pathology that is not attainable using animal models. This study will improve our understanding of the pathological mechanisms underlying HCM and could eventually lead to improved treatment options for HCM patients. Future efforts will be aimed at establishing high-throughput cellular platforms for analysis and compound testing to screen drugs for safety and efficacy.
Competitiondate
201302
Approvedterm2
2 yrs 10 mths
Pinamesdelim
Mandegar, Mohammad A
Approvedterm
2 ans 10 mois
Cihrcontribution2
~ $141,667~ $0~